Daily Stock Analysis, CHRS, Coherus BioSciences Inc, priceseries

Coherus BioSciences Inc. Daily Stock Analysis
Stock Information
Open
21.95
Close
21.57
High
22.05
Low
21.30
Previous Close
21.85
Daily Price Gain
-0.28
YTD High
29.59
YTD High Date
Jan 5, 2017
YTD Low
20.88
YTD Low Date
Feb 23, 2017
YTD Price Change
-6.43
YTD Gain
-22.95%
52 Week High
31.98
52 Week High Date
Sep 16, 2016
52 Week Low
14.00
52 Week Low Date
Jun 27, 2016
52 Week Price Change
2.75
52 Week Gain
14.58%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 14. 2015
22.63
May 29. 2015
24.63
10 Trading Days
8.85%
Link
LONG
Jun 5. 2015
25.11
Jun 24. 2015
26.75
13 Trading Days
6.53%
Link
LONG
Jul 9. 2015
29.87
Jul 24. 2015
35.54
11 Trading Days
18.97%
Link
LONG
Oct 23. 2015
24.66
Nov 11. 2015
28.55
13 Trading Days
15.79%
Link
LONG
Mar 1. 2016
15.02
Mar 15. 2016
18.45
10 Trading Days
22.86%
Link
LONG
Jul 8. 2016
17.22
Aug 24. 2016
29.04
33 Trading Days
68.66%
Link
LONG
Oct 12. 2016
27.88
Oct 26. 2016
29.73
10 Trading Days
6.65%
Link
LONG
Feb 27. 2017
22.90
Mar 8. 2017
24.15
7 Trading Days
5.47%
Link
Company Information
Stock Symbol
CHRS
Exchange
NasdaqGM
Company URL
http://www.coherus.com
Company Phone
(650) 649-3530
CEO
Denny M. Lanfear
Headquarters
California
Business Address
C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA 94065
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001512762
About

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, whi...

Description

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the prevention of chemotherapy-induced neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis, as well as to treat ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis; and CHS-5217, a bevacizumab biosimilar candidate to treat metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and ulcerative colitis. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; license agreement with Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; distribution agreement with Orox Pharmaceuticals B.V.; license agreement with Genentech, Inc.; and license agreements with Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.